NF Midwest Collaborates to Fund NF2 Gene Therapy Research
NF Midwest, NF Northeast and NF2 BioSolutions have joined forces to fund an NF2 Gene Therapy Research Study at the Mueller Lab at the Gene Therapy Center, UMass Medical School. This $65,000 grant will be used to design, manufacture and test potential gene therapy vectors for Neurofibromatosis Type 2. Dr. Katharina Meijboom, a postdoctoral researcher, is heading up the project. Her research will focus on several different approaches and will be tested in both cell lines and mouse models. The Mueller Laboratory at the UMass Gene Therapy Center has a long history of using recombinant AAV as a platform for gene therapy in a plethora of different diseases, ranging from liver diseases to central nervous system diseases, such as ALS.
The NF Midwest Scholarship Program is proud to celebrate another year of supporting students with neurofibromatosis as they work toward their educational dreams. Each year, NF Midwest awards scholarships to students across our six-state region. These students are pursuing their goals while also navigating life with NF, and we are honored to play a small... Read More
Every treatment that exists today: every medication, every therapy, every breakthrough, started somewhere. It started with a question, a hypothesis, and eventually, a clinical trial. May 20 is National Clinical Trials Day, a moment to recognize the remarkable system that turns scientific ideas into real-world answers. For the NF community (patients, families, caregivers, and advocates)... Read More
Responses